1613 related articles for article (PubMed ID: 18610675)
1. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Singla R; Gupta S; Gupta R; Arora VK
Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
de Kantor IN; Barrera L
Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
[TBL] [Abstract][Full Text] [Related]
8. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
10. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
11. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
[TBL] [Abstract][Full Text] [Related]
12. [The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
Iwanaga T; Yokota K; Kishikawa R; Ikeda T; Tsurutani H; Hirose T; Nishima S
Kekkaku; 1997 Jan; 72(1):9-13. PubMed ID: 9038010
[TBL] [Abstract][Full Text] [Related]
13. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
14. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
[TBL] [Abstract][Full Text] [Related]
15. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Mizutani H; Horiba M; Shindoh J; Kimura T; Son M; Wakahara K
Kekkaku; 2001 Oct; 76(10):667-72. PubMed ID: 11712388
[TBL] [Abstract][Full Text] [Related]
17. [A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine].
Fujita J; Sunada K; Hayashi H; Hayashihara K; Saito T
Kekkaku; 2008 Jan; 83(1):21-5. PubMed ID: 18283911
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
Mirsaeidi SM; Tabarsi P; Khoshnood K; Pooramiri MV; Rowhani-Rahbar A; Mansoori SD; Masjedi H; Zahirifard S; Mohammadi F; Farnia P; Masjedi MR; Velayati AA
Int J Infect Dis; 2005 Nov; 9(6):317-22. PubMed ID: 16183321
[TBL] [Abstract][Full Text] [Related]
19. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands.
Geerligs WA; Van Altena R; De Lange WCM ; Van Soolingen D; Van Der Werf TS
Int J Tuberc Lung Dis; 2000 Aug; 4(8):758-64. PubMed ID: 10949328
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study.
Subhash HS; Ashwin I; Jesudason MV; Abharam OC; John G; Cherian AM; Thomas K
Indian J Chest Dis Allied Sci; 2003; 45(2):97-103. PubMed ID: 12715931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
